All Providers

Professor Robert Brown is Chair in Translational Oncology and Head of Division of Cancer within the Department of Surgery and Cancer at Imperial College, where he heads the Epigenetics Unit. His post is a joint appointment between Imperial College London and Institute of Cancer Research where he is the Epigenetics Team Leader in the Section of Molecular Pathology. Bob is Principal Investigator of a Cancer Research UK research programme, Drug Resistance and Epigenetic Mechanisms, and is a joint Principle Investigator of the Imperial Experimental Cancer Medicine Centre. He moved to London in 2007 after working for nearly 20 years at the CRUK Beatson Laboratories in Glasgow where he was Director of Laboratory Research in the Centre for Oncology and Applied Pharmacology. He obtained his BSc in Biological Sciences (Genetics) at Edinburgh University, his PhD at MRC Radiobiology Unit, Harwell, and his Post-doc at the German Cancer Research Centre, Heidelberg.

He has provided key insight into epigenetic mechanisms involved in tumorigenesis and resistance to chemotherapy, particularly in ovarian cancer. Recent areas of his research include; identifying novel epigenetic targets in ovarian and breast cancer, characterising histone marks and DNA methylation in breast and ovarian tumours as risk, prognostic and/or predictive biomarkers, and development of novel histone methyltransferase inhibitors.

He is Chair of the NCRI Biomarker and Imaging Clinical Studies Group whose remit is to facilitate and support biomarker and imaging studies in UK clinical trials. He is Deputy-Chair of CR-UK New Agents Committee and member of MRC Molecular and Cellular Medicine Board.

James D. Brenton is a senior group leader at the Cancer Research UK (CR-UK) Cambridge Institute and leads the Functional Genomics of Ovarian Cancer laboratory. He qualified in medicine from University College London in 1988 and trained in medical oncology at the Royal Marsden Hospital, Princess Margaret Hospital, Toronto and the Department of Oncology, University of Cambridge. He has been an honorary consultant in medical oncology at Cambridge University Hospitals NHS Foundation Trust since 2001. His PhD work was carried out at the Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Developmental Biology and he held a Cancer Research UK Senior Clinical Research Fellow from 2001–2006 at the Hutchison/MRC Research Centre.

His research focuses on the identification of prognostic and predictive markers for therapy in ovarian cancer and identifying mechanisms of drug resistance, with particular emphasis on the genomic profiling of clinical samples and bioinformatic analysis.

He is the chair of the Informatics Advisory Group for the national CR-UK Stratified Medicine Programme and was previously Vice-Chair of the CR-UK Biomarkers and Imaging Discovery and Development Committee. He is a member of the international Ovarian Tumor Tissue Analysis (OTTA) Consortium project approval committee, the SGCTG Protocol Review Committee, NCRI ovarian cancer subgroup and the CR-UK Clinical Fellows Mentor Panel.

Professor Ignace Vergote is Chairman of the Leuven Cancer Institute and Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, Belgium. He initially trained in Obstetrics and Gynaecology at the University of Antwerp, Belgium, before specialising in Gynaecologic Oncology in the Department of Gynaecologic Oncology at the Norwegian Radium Hospital, where he later became staff member and in 1991 deputy chairman.

Professor Vergote is currently Chairman of the Belgian & Luxemburg Gynaecological Oncology Group (BGOG), and Chairman of the Protocol committee of European Organization for Research, and Treatment of Cancer -Gynecologic Cancer Group (EORTC-GCG), and President of the Society of Robotic European Gynaecological Surgery (SERGS). Professor Vergote was the founder and first chairman of ENGOT from 2007 until 2012. In 2013 he was Chairman of the Board of Medical Chairmen of the University Hospital Leuven. Since 2014 he is member of the Board of Directors of the University Hospital Leuven.

He has been Chairman of the EORTC-GCG from 1997 to 2003, and served as President of the European Society of Gynaecological Oncology (ESGO) for the period 2003-2005. For the period 2006-2008 he was the President of the International Gynecologic Cancer Society (IGCS). He has been Chairman of the Flemish Society of Obstetrics and Gynaecology from 2008 to 2013. He was founder and first chairman of the European Network of Gynaecological Oncological Trial groups (ENGOT) from 2007 tot 2012.

He received in 2004 the Wertheim price in Austria and the COBRA price for surgical expertise in the Netherlands. In 2008 he became Honorary Member of the Finnish Society of Gynaecology and Obstetrics. In 2012 he became Honorary Member of the American College of Surgeons. 

Professor Vergote’s main areas of clinical and translational research focus on ovarian and uterine cancer. He has authored more than 635 original full papers in peer-reviewed journals, together with 50 book chapters, and edited several books on Gynaecological Oncology. He is Editor of the European Journal of Cancer , and past-Associate Editor of Gynecologic Oncology and the International Journal of Gynaecological Cancer.

Franca Esposito is Professor of Biochemistry, School of Medicine, University of Naples Federico II, Italy.

After graduating in medicine at the University of Naples Federico II, Professor Esposito did her residency in Clinical Biochemistry and Molecular Biology at the same University. Formerly, a visiting scientist, Department of Biochemistry, University of Missouri, Columbia, USA and a post-doctoral assistant at the Department of Biochemistry and Molecular Biology, University of Cincinnati, USA.

At the School of Medicine, University of Naples Federico II, Professor Esposito is the Coordinator for Biochemistry courses and President of the BS degree course for Medical Laboratory Technicians.

Her research activity has focused on the study of the redox regulation of gene expression and effects of reactive oxygen species on the: i) activity of some transcription factors; ii) expression of cell cycle regulatory proteins and iii) regulation of mitogenic signal transduction.

Professor Esposito's present research activity includes the study of TRAP1, a novel antiapoptotic gene involved in the resistance to anticancer therapy. She is working on the validation of TRAP1 as a new biomarker and drug target candidate in multiple human cancers and chemoresistance.

Gordon Moore is a Professor of Population Medicine (on leave) at Harvard Medical School.

He was one of the founding group of Harvard Community Health Plan and rose to become the Medical Director and Chief Operating Officer prior to the organization’s split into Harvard Vanguard and Harvard Pilgrim Health Care.

Following his move to the Medical School, he was responsible for the design and development of the New Pathway, Harvard’s ground-breaking student directed curriculum. He designed and started the Harvard Vanguard-Brigham Primary Care Medical Residency program, which is now one of the most highly sought-after in the country.

In addition to educational, health services, and health care management research and development, Gordon has consulted widely in educational strategy and health care system design and management.

He has over 100 publications.

He was the recipient of the 2008 President’s Award from the Royal College of General Practice in the United Kingdom, in recognition of his role in supporting primary care worldwide.

Dr Mark Cohen provides a comprehensive and personally-tailored service for patients with endocrine and diabetic conditions.

Dr Cohen qualified in medicine from the University of Birmingham in 1994 with a 1st class honours degree in Physiology. After becoming a member of the Royal College of Physicians in 1998 he returned to London to become a Medical Research Council Clinical Research Fellow at Hammersmith Hospital under the supervision of Professor Steve Bloom.

His original research on the role of the gut hormones PYY, oxyntomodulin and ghrelin in the regulation of food intake culmunated in a PhD in Physiology, awarded in 2005.

Obesity surgery is believed to act through alterations in the release of these appetite-regulating hormones.

Dr Cohen was appointed Consultant in Endocrinology and Diabetes at Barnet Hospital in 2006 and continues to have a specialist interest in the clinical management of obesity.

Ms Lena Andersson M.D., Dr.med., founded the Anelca Clinic in 1998, and recruited further Specialists to the team, including Hand- and Maxillofacial Surgical Specialists.

Ms Andersson has been a Consultant Plastic Surgeon since 1993. She originally trained at the Karolinska Institute, Stockholm. She received her specialist training in Aesthetic- and Plastic Surgery in Sweden, Switzerland and the USA, before being appointed as Consultant Plastic Surgeon at St Bartholomew’s Hospital and the Royal London Hospital in 1995, when she also commenced her private practice in London.

Dr. Al-Rubeyi was born in Baghdad, Iraq and is fluent in both Arabic and English.

Trained in medicine in the UK and has been a Paediatric Consultant since 1994.

Dr Al-Rubeyi has a wide experience in general Paediatrics, her specialist training included Paediatric Cardiology and intensive care at Great Ormond Street Hospital as well as Neuromuscular, Respiratory and Neonatology at the Hammersmith Hospital, Imperial College and the University College Hospital.

She has a special interest in allergy and respiratory medical conditions especially asthma and eczema.

She started running the private practice in 2006 meanwhile maintaining her commitment to the NHS, at present, she is practicing at Harley Street Clinic whilst committing one session a week at the allergy department at Imperial College, St. Marys Hospital.

Dr Al-Rubeyi currently manages and consults at the Harley Street Paediatrics, based at 78 Harley Street, she believes in a holistic approach to the management of acute and chronic medical conditions, upholding the patient and their family as the number one priority. Further to her reputation, the doctor has released many publications in the medical circle as well as providing teaching at various institutes Dr. Al-Rubeyi is a fellow of The Royal College of Paediatric and Child Health and member of The Royal college of Physician.

Dr Abraham trained at Kings College Hospital, St Mary's Hospital and St Bartholomew's Hospital as an academic physician turning to full time private practice in 1984. He founded London Medical in 1991.

His special interests are diabetes and endocrinology, lipid disorders and heart disease prevention.

Mr Desai studied medicine at University of Glasgow from1970 to 1975 (MBChB).

After initial training in Surgery in the West of Scotland, and passing his surgical examinations, he became Fellow of the Royal College of Surgeons and Physicians of Glasgow in 1979.

His cardiac surgical training commenced and continued after moving to Hammersmith Hospital in London in 1982. After a further 4 years of training and research he passed the Cardiothoracic Speciality examination and was made a Fellow of the Royal College of Surgeons of Edinburgh in 1986.

Mr Desai was appointed Senior Registrar at Hammersmith, Harefield and Middlesex Hospitals and in 1990, he was visiting fellow at Barnes Hospital (St. Louis, USA) where he learnt surgery for cardiac arrhythmias.

He was appointed Consultant Cardio-Thoracic Surgeon at King’s College Hospital in 1990 where he continues to work today.

He has been trained in Adult and Paediatric Cardiac and Thoracic Surgery and Transplantation but presently practices as an Adult Cardiac Surgeon.